St Co. Ltd Dong-A Acquires 2,544,530 Shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Stock

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) major shareholder St Co. Ltd Dong-A bought 2,544,530 shares of the company’s stock in a transaction that occurred on Sunday, June 23rd. The shares were bought at an average price of $3.13 per share, for a total transaction of $7,964,378.90. Following the completion of the acquisition, the insider now owns 5,348,229 shares in the company, valued at approximately $16,739,956.77. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

NeuroBo Pharmaceuticals Stock Performance

Shares of NASDAQ NRBO opened at $4.83 on Thursday. NeuroBo Pharmaceuticals, Inc. has a fifty-two week low of $2.89 and a fifty-two week high of $6.75. The business has a 50 day moving average price of $3.88 and a two-hundred day moving average price of $4.10.

NeuroBo Pharmaceuticals (NASDAQ:NRBO) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.37). As a group, sell-side analysts expect that NeuroBo Pharmaceuticals, Inc. will post -4.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Maxim Group initiated coverage on NeuroBo Pharmaceuticals in a report on Wednesday, May 8th. They set a “buy” rating and a $10.00 target price on the stock.

NeuroBo Pharmaceuticals Company Profile

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.